Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
4.070
-0.830 (-16.94%)
At close: Mar 20, 2026, 4:00 PM EDT
4.390
+0.320 (7.86%)
After-hours: Mar 20, 2026, 6:03 PM EDT

Aardvark Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2023
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
10.775.312.172.7
Research & Development
42.717.364.487.17
Other Operating Expenses
-0.120.761.49
Total Operating Expenses
53.4722.797.4211.36
Operating Income
-53.47-22.79-7.42-11.36
Interest Income
4.732.411.420.12
Other Non-Operating Income (Expense)
-0.03-0.22-1.22-2.32
Total Non-Operating Income (Expense)
4.72.20.21-2.2
Pretax Income
-48.77-20.59-7.21-13.56
Net Income
-48.77-20.59-7.21-13.56
Net Income to Common
-48.77-20.59-7.21-13.56
Shares Outstanding (Basic)
15444
Shares Outstanding (Diluted)
15444
Shares Change (YoY)
273.85%0.90%1.78%-
EPS (Basic)
-4.30-5.15-1.82-3.49
EPS (Diluted)
-4.30-5.15-1.82-3.49
Free Cash Flow
-45.19-18.2-5.82-5.82
Free Cash Flow Per Share
-2.98-4.55-1.47-1.50
EBITDA
-53.44-22.77-7.42-11.36
EBIT
-53.47-22.79-7.42-11.36
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q